Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones

Apr 30

DJ Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. $(INCY)$ rose 1.39% to $99.10 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.04% to 7,135.95 and Dow Jones Industrial Average falling 0.57% to 48,861.81.

This was the stock's third consecutive day of gains.

Incyte Corp. closed 11.75% below its 52-week high of $112.29, which the company reached on January 7th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. $(ALNY)$ fell 0.30% to $301.19, Bio-Techne Corp. $(TECH)$ fell 2.92% to $51.95, and BioMarin Pharmaceutical Inc. $(BMRN)$ rose 1.71% to $54.21.

Trading volume (2.2 M) eclipsed its 50-day average volume of 1.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled April 29, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

April 29, 2026 17:07 ET (21:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2631245005"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631245005\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631245005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631245005","market":"us","top_or_hot":-1,"title":"Incyte Corp. Stock Outperforms Competitors On Strong Trading Day","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nDJ Incyte Corp. Stock Outperforms Competitors On Strong Trading Day\n</p>\n<p>\n  This article was automatically generated by MarketWatch using technology from Automated Insights. \n</p>\n<p>\n     Shares of Incyte Corp. <a href=\"https://laohu8.com/S/INCY\">$(INCY)$</a> rose 1.39% to $99.10 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&amp;P 500 Index  falling 0.04% to 7,135.95 and Dow Jones Industrial Average  falling 0.57% to 48,861.81. \n</p>\n<p>\n     This was the stock's third consecutive day of gains. \n</p>\n<p>\n     Incyte Corp. closed 11.75% below its 52-week high of $112.29, which the company reached on January 7th. \n</p>\n<p>\n     The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/ALNY\">$(ALNY)$</a> fell 0.30% to $301.19, Bio-Techne Corp. <a href=\"https://laohu8.com/S/TECH\">$(TECH)$</a> fell 2.92% to $51.95, and BioMarin Pharmaceutical Inc. <a href=\"https://laohu8.com/S/BMRN\">$(BMRN)$</a> rose 1.71% to $54.21. \n</p>\n<p>\n     Trading volume (2.2 M) eclipsed its 50-day average volume of 1.6 M. \n</p>\n<p>\n     Data source: Dow Jones Market Data, FactSet. Data compiled April 29, 2026. \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 17:07 ET (21:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Corp. Stock Outperforms Competitors On Strong Trading Day</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Corp. Stock Outperforms Competitors On Strong Trading Day\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-30 05:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nDJ Incyte Corp. Stock Outperforms Competitors On Strong Trading Day\n</p>\n<p>\n  This article was automatically generated by MarketWatch using technology from Automated Insights. \n</p>\n<p>\n     Shares of Incyte Corp. <a href=\"https://laohu8.com/S/INCY\">$(INCY)$</a> rose 1.39% to $99.10 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&amp;P 500 Index  falling 0.04% to 7,135.95 and Dow Jones Industrial Average  falling 0.57% to 48,861.81. \n</p>\n<p>\n     This was the stock's third consecutive day of gains. \n</p>\n<p>\n     Incyte Corp. closed 11.75% below its 52-week high of $112.29, which the company reached on January 7th. \n</p>\n<p>\n     The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/ALNY\">$(ALNY)$</a> fell 0.30% to $301.19, Bio-Techne Corp. <a href=\"https://laohu8.com/S/TECH\">$(TECH)$</a> fell 2.92% to $51.95, and BioMarin Pharmaceutical Inc. <a href=\"https://laohu8.com/S/BMRN\">$(BMRN)$</a> rose 1.71% to $54.21. \n</p>\n<p>\n     Trading volume (2.2 M) eclipsed its 50-day average volume of 1.6 M. \n</p>\n<p>\n     Data source: Dow Jones Market Data, FactSet. Data compiled April 29, 2026. \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 17:07 ET (21:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631245005","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631245005","pubTimestamp":1777496820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Incyte Corp.  rose 1.39% to $99.10 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.04% to 7,135.95 and Dow Jones Industrial Average  falling 0.57% to 48,861.81.This was the stock's third consecutive day of gains.Incyte Corp. closed 11.75% below its 52-week high of $112.29, which the company reached on January 7th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc.  fell 0.30% to $301.19, Bio-Techne Corp.  fell 2.92% to $51.95, and BioMarin Pharmaceutical Inc.  rose 1.71% to $54.21.Trading volume  eclipsed its 50-day average volume of 1.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 29, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from D","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗"},"translate_title":"Incyte Corp.股票在强劲交易日表现优于竞争对手","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1.5},"content_text":"DJ Incyte Corp. Stock Outperforms Competitors On Strong Trading Day\n\n\n  This article was automatically generated by MarketWatch using technology from Automated Insights. \n\n\n     Shares of Incyte Corp. $(INCY)$ rose 1.39% to $99.10 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.04% to 7,135.95 and Dow Jones Industrial Average  falling 0.57% to 48,861.81. \n\n\n     This was the stock's third consecutive day of gains. \n\n\n     Incyte Corp. closed 11.75% below its 52-week high of $112.29, which the company reached on January 7th. \n\n\n     The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. $(ALNY)$ fell 0.30% to $301.19, Bio-Techne Corp. $(TECH)$ fell 2.92% to $51.95, and BioMarin Pharmaceutical Inc. $(BMRN)$ rose 1.71% to $54.21. \n\n\n     Trading volume (2.2 M) eclipsed its 50-day average volume of 1.6 M. \n\n\n     Data source: Dow Jones Market Data, FactSet. Data compiled April 29, 2026. \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 17:07 ET (21:07 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}